Why am I not losing weight on my GLP-1?

Work through the checklist in order — most “non-responders” find their answer in the first four items: 1. Are you past the starter doses? 0.25–0.5 mg semaglutide and 2.5 mg tirzepatide are tolerance-building steps. Judging the drug there is like judging coffee by decaf. Real assessment starts ≈4+ weeks at a mid-ladder dose. 2. Where are calories sneaking in? GLP-1s suppress meal appetite, but lattes, juice, alcohol, and constant grazing partially bypass fullness signaling. A blunt 3-day food log (everything, including drinks) finds the leak more often than anything else on this list. 3. Is there headroom on dose? If appetite suppression is weak and side effects are minimal, you may simply be under-dosed — the dose-response curve is real. That’s a titration conversation with your prescriber. 4. Is the appetite effect present at all? This is the key diagnostic split. Some suppression but no loss → intake problem (#2). Zero suppression at meaningful doses → drug-delivery problem (#5) or true non-response (#6). 5. If you’re on compounded or sublingual: absorption and formulation quality are legitimate questions. Sublingual non-response in particular warrants a switch to injections before concluding anything (why). For injections: check technique, storage (excess heat degrades peptides), and expiration. 6. True non-response.. It’s biology, not failure. The move is switching molecules — semaglutide non-responders often respond well to tirzepatide — or adding a different mechanism entirely (your clinician’s call). Also worth ruling out: thyroid issues, weight-promoting medications (some antidepressants, antipsychotics, steroids, insulin regimens), and undiagnosed insulin resistance — a short clinician visit covers all three.